Prospects for Development and Potential Impact of a Vaccine Against Congenital Cytomegalovirus (CMV) Infection

Journal of Pediatrics

Volumn 151, Issue 6, 2007, Pages 564-570

  Schleiss, Mark R ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOMEGALOVIRUS VACCINE;

ARTICLE; CLINICAL TRIAL; CONGENITAL INFECTION; CONGENITAL RUBELLA SYNDROME; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; DRUG SAFETY; GRAFT REJECTION; HEALTH PROGRAM; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOGENICITY; MENTAL DEFICIENCY; NERVE CELL DIFFERENTIATION; PASSIVE IMMUNIZATION; PERCEPTION DEAFNESS; PNEUMONIA; PREGNANCY; PRIORITY JOURNAL; RETINITIS;

CLINICAL TRIALS AS TOPIC; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; CYTOMEGALOVIRUS VACCINES; FEMALE; HUMANS; IMMUNIZATION, PASSIVE; INFANT, NEWBORN; PREGNANCY; VACCINES, DNA; VIRION;

EID: 36148967345     PISSN: 00223476     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpeds.2007.07.015     Document Type: Article

References (88)

1. Griffiths P.D. Happy anniversary for human cytomegalovirus. Rev Med Virol 16 (2006) 349-352
2. Boeckh M., Fries B., and Nichols W.G. Recent advances in the prevention of CMV infection and disease after hematopoietic stem cell transplantation. Pediatr Transplant 8 Suppl 5 (2004) 19-27
3. Boeckh M., and Riddell S.R. Immunologic predictors of late cytomegalovirus disease after solid organ transplantation: an elusive goal?. J Infect Dis 195 (2007) 615-617
4. Reischig T., Jindra P., Svecova M., Kormunda S., Opatrny Jr. K., and Treska V. The impact of cytomegalovirus disease and asymptomatic infection on acute renal allograft rejection. J Clin Virol 36 (2006) 146-151
5. Whitley R.J. Congenital cytomegalovirus infection: epidemiology and treatment. Adv Exp Med Biol 549 (2004) 155-160
6. Ross D.S., Dollard S.C., Victor M., Sumartojo E., and Cannon M.J. The epidemiology and prevention of congenital cytomegalovirus infection and disease: activities of the Centers for Disease Control and Prevention Workgroup. J Womens Health (Larchmt) 15 (2006) 224-229
7. Stagno S., Pass R.F., Cloud G., Britt W.J., Henderson R.E., Walton P.D., Veren D.A., Page F., and Alford C.A. Primary cytomegalovirus infection in pregnancy: incidence, transmission to fetus, and clinical outcome. JAMA 256 (1986) 1904-1908
8. Pass R.F., Hutto C., Ricks R., and Cloud G.A. Increased rate of cytomegalovirus infection among parents of children attending day-care centers. N Engl J Med 314 (1986) 1414-1418
9. Adler S.P., Finney J.W., Manganello A.M., and Best A.M. Prevention of child-to-mother transmission of cytomegalovirus among pregnant women. J Pediatr 145 (2004) 485-491
10. Fowler K.B., Stagno S., Pass R.F., Britt W.J., Boll T.J., and Alford C.A. The outcome of congenital cytomegalovirus infection in relation to maternal antibody status. N Engl J Med 326 (1992) 663-667
11. Fowler K.B., Stagno S., and Pass R.F. Maternal immunity and prevention of congenital cytomegalovirus infection. JAMA 289 (2003) 1008-1011
12. Pass R.F., Fowler K.B., Boppana S.B., Britt W.J., and Stagno S. Congenital cytomegalovirus infection following first trimester maternal infection: symptoms at birth and outcome. J Clin Virol 35 (2006) 216-220
13. Lazzarotto T., Gabrielli L., Lanari M., Guerra B., Bellucci T., Sassi M., and Landini M.P. Congenital cytomegalovirus infection: recent advances in the diagnosis of maternal infection. Hum Immunol 65 (2004) 410-415
14. Bodeus M., Van Ranst M., Bernard P., Hubinont C., and Goubau P. Anticytomegalovirus IgG avidity in pregnancy: a 2-year prospective study. Fetal Diagn Ther 17 (2002) 362-366
15. Arav-Boger R., Battaglia C.A., Lazzarotto T., Gabrielli L., Zong J.C., Hayward G.S., Diener-West M., and Landini M.P. Cytomegalovirus (CMV)-encoded UL144 (truncated tumor necrosis factor receptor) and outcome of congenital CMV infection. J Infect Dis 194 (2006) 464-473
16. Arvin A.M., Fast P., Myers M., Plotkin S., Rabinovich R., and National Vaccine Advisory Committee. Vaccine development to prevent cytomegalovirus disease: report from the National Vaccine Advisory Committee. Clin Infect Dis 39 (2004) 233-239
17. Pass R.F. Immunization strategy for prevention of congenital cytomegalovirus infection. Infect Agents Dis 5 (1996) 240-244
18. Fowler K.B., McCollister F.P., Dahle A.J., Boppana S., Britt W.J., and Pass R.F. Progressive and fluctuating sensorineural hearing loss in children with asymptomatic congenital cytomegalovirus infection. J Pediatr 130 (1997) 624-630
19. Williamson W.D., Demmler G.J., Percy A.K., and Catlin F.I. Progressive hearing loss in infants with asymptomatic congenital cytomegalovirus infection. Pediatrics 90 (1992) 862-866
20. Fowler K.B., Dahle A.J., Boppana S.B., and Pass R.F. Newborn hearing screening: will children with hearing loss caused by congenital cytomegalovirus infection be missed?. J Pediatr 135 (1999) 60-64
21. Nance W.E., Lim B.G., and Dodson K.M. Importance of congenital cytomegalovirus infections as a cause for pre-lingual hearing loss. J Clin Virol 35 (2006) 221-225
22. Dolan A., Cunningham C., Hector R.D., Hassan-Walker A.F., Lee L., Addison C., Dargan D.J., McGeoch D.J., Gatherer D., Emery V.C., Griffiths P.D., Sinzger C., McSharry B.P., Wilkinson G.W., and Davison A.J. Genetic content of wild-type human cytomegalovirus. J Gen Virol 85 (2004) 1301-1312
23. Varnum S.M., Streblow D.N., Monroe M.E., Smith P., Auberry K.J., Pasa-Tolic L., Wang D., Camp II D.G., Rodland K., Wiley S., Britt W., Shenk T., Smith R.D., and Nelson J.A. Identification of proteins in human cytomegalovirus (HCMV) particles: the HCMV proteome. J Virol 78 (2004) 10960-10966
24. Britt W.J., Vugler L., Butfiloski E.J., and Stephens E.B. Cell surface expression of human cytomegalovirus (HCMV) gp55-116 (gB): use of HCMV-recombinant vaccinia virus-infected cells in analysis of the human neutralizing antibody response. J Virol 64 (1990) 1079-1085
25. Marshall G.S., Stout G.G., Knights M.E., Rabalais G.P., Ashley R., Miller H., and Rossier E. Ontogeny of glycoprotein gB-specific antibody and neutralizing activity during natural cytomegalovirus infection. J Med Virol 43 (1994) 77-83
26. Kniess N., Mach M., Fay J., and Britt W.J. Distribution of linear antigenic sites on glycoprotein gp55 of human cytomegalovirus. J Virol 65 (1991) 138-146
27. Marshall G.S., Rabalais G.P., Stout G.G., and Waldeyer S.L. Antibodies to recombinant-derived glycoprotein B after natural human cytomegalovirus infection correlate with neutralizing activity. J Infect Dis 165 (1992) 381-384
28. Kari B., and Gehrz R. Analysis of human antibody responses to human cytomegalovirus envelope glycoproteins found in two families of disulfide linked glycoprotein complexes designated gC-I and gC-II. Arch Virol 114 (1990) 213-228
29. Mach M., Kropff B., Dal Monte P., and Britt W. Complex formation by human cytomegalovirus glycoproteins M (gpUL100) and N (gpUL73). J Virol 74 (2000) 11881-11892
30. Mach M., Kropff B., Kryzaniak M., and Britt W. Complex formation by glycoproteins M and N of human cytomegalovirus: structural and functional aspects. J Virol 79 (2005) 2160-2170
31. Urban M., Klein M., Britt W.J., Hassfurther E., and Mach M. Glycoprotein H of human cytomegalovirus is a major antigen for the neutralizing humoral immune response. J Gen Virol 77 (1996) 1537-1547
32. Simpson J.A., Chow J.C., Baker J., Avdalovic N., Yuan S., Au D., Co M.S., Vasquez M., Britt W.J., and Coelingh K.L. Neutralizing monoclonal antibodies that distinguish three antigenic sites on human cytomegalovirus glycoprotein H have conformationally distinct binding sites. J Virol 67 (1993) 489-496
33. Shimamura M., Mach M., and Britt W.J. Human cytomegalovirus infection elicits a glycoprotein M (gM)/gN-specific virus-neutralizing antibody response. J Virol 80 (2006) 4591-4600
34. McLaughlin-Taylor E., Pande H., Forman S.J., Tanamachi B., Li C.R., Zaia J.A., Greenberg P.D., and Riddell S.R. Identification of the major late human cytomegalovirus matrix protein pp65 as a target antigen for CD8+ virus-specific cytotoxic T lymphocytes. J Med Virol 43 (1994) 103-110
35. Wills M.R., Carmichael A.J., Mynard K., Jin X., Weekes M.P., Plachter B., and Sissons J.G. The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T-cell receptor usage of pp65-specific CTL. J Virol 70 (1996) 7569-7579
36. Lacey S.F., Gallez-Hawkins G., Crooks M., Martinez J., Senitzer D., Forman S.J., Spielberger R., Zaia J.A., and Diamond D.J. Characterization of cytotoxic function of CMV-pp65-specific CD8+ T-lymphocytes identified by HLA tetramers in recipients and donors of stem-cell transplants. Transplantation 74 (2002) 722-732
37. Kern F., Bunde T., Faulhaber N., Kiecker F., Khatamzas E., Rudawski I.M., Pruss A., Gratama J.W., Volkmer-Engert R., Ewert R., Reinke P., Volk H.D., and Picker L.J. Cytomegalovirus (CMV) phosphoprotein 65 makes a large contribution to shaping the T cell repertoire in CMV-exposed individuals. J Infect Dis 185 (2002) 1709-1716
38. Gyulai Z., Endresz V., Burian K., Pincus S., Toldy J., Cox W.I., Meric C., Plotkin S., Gonczol E., and Berencsi K. Cytotoxic T lymphocyte (CTL) responses to human cytomegalovirus pp65, IE1-Exon4, gB, pp150, and pp28 in healthy individuals: reevaluation of prevalence of IE1-specific CTLs. J Infect Dis 181 (2000) 1537-1546
39. Gibson L., Piccinini G., Lilleri D., Revello M.G., Wang Z., Markel S., Diamond D.J., and Luzuriaga K. Human cytomegalovirus proteins pp65 and immediate early protein 1 are common targets for CD8+ T cell responses in children with congenital or postnatal human cytomegalovirus infection. J Immunol 172 (2004) 2256-2264
40. Wang Z., La Rosa C., Maas R., Ly H., Brewer J., Mekhoubad S., Daftarian P., Longmate J., Britt W.J., and Diamond D.J. Recombinant modified vaccinia virus Ankara expressing a soluble form of glycoprotein B causes durable immunity and neutralizing antibodies against multiple strains of human cytomegalovirus. J Virol 78 (2004) 3965-3976
41. La Rosa C., Wang Z., Lacey S.F., Markel S.F., Sharma M.C., Martinez J., Lalimarmo M.M., and Diamond D.J. Characterization of host immunity to cytomegalovirus pp150 (UL32). Hum Immunol 66 (2005) 116-126
42. Elkington R., Walker S., Crough T., Menzies M., Tellam J., Bharadwaj M., and Khanna R. Ex vivo profiling of CD8+-T-cell responses to human cytomegalovirus reveals broad and multispecific reactivities in healthy virus carriers. J Virol 77 (2003) 5226-5240
43. Sylwester A.W., Mitchell B.L., Edgar J.B., Taormina C., Pelte C., Ruchti F., Sleath P.R., Grabstein K.H., Hosken N.A., Kern F., Nelson J.A., and Picker L.J. Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects. J Exp Med 202 (2005) 673-685
44. Neff B.J., Weibel R.E., Buynak E.B., McLean A.A., and Hilleman M.R. Clinical and laboratory studies of live cytomegalovirus vaccine Ad-169. Proc Soc Exp Biol Med 160 (1979) 32-37
45. Gonczol E., Ianacone J., Furlini G., Ho W., and Plotkin S.A. Humoral immune response to cytomegalovirus Towne vaccine strain and to Toledo low-passage strain. J Infect Dis 159 (1989) 851-859
46. Adler S.P., Starr S.E., Plotkin S.A., Hempfling S.H., Buis J., Manning M.L., and Best A.M. Immunity induced by primary human cytomegalovirus infection protects against secondary infection among women of childbearing age. J Infect Dis 171 (1995) 26-32
47. Adler S.P., Hempfling S.H., Starr S.E., Plotkin S.A., and Riddell S. Safety and immunogenicity of the Towne strain cytomegalovirus vaccine. Pediatr Infect Dis J 17 (1998) 200-206
48. Gehrz R.C., Christianson W.R., Linner K.M., Groth K.E., and Balfour Jr. H.H. Cytomegalovirus vaccine: specific humoral and cellular immune responses in human volunteers. Arch Intern Med 140 (1980) 936-939
49. Starr S.E., Glazer J.P., Friedman H.M., Farquhar J.D., and Plotkin S.A. Specific cellular and humoral immunity after immunization with live Towne strain cytomegalovirus vaccine. J Infect Dis 143 (1981) 585-589
50. Fleisher G.R., Starr S.E., Friedman H.M., and Plotkin S.A. Vaccination of pediatric nurses with live attenuated cytomegalovirus. Am J Dis Child 136 (1982) 294-296
51. Plotkin S.A., Starr S.E., Friedman H.M., Gonczol E., and Weibel R.E. Protective effects of Towne cytomegalovirus vaccine against low-passage cytomegalovirus administered as a challenge. J Infect Dis 159 (1989) 860-865
52. Quinnan Jr. G.V., Delery M., Rook A.H., Frederick W.R., Epstein J.S., Manischewitz J.F., Jackson L., Ramsey K.M., Mittal K., Plotkin S.A., et al. Comparative virulence and immunogenicity of the Towne strain and a nonattenuated strain of cytomegalovirus. Ann Intern Med 101 (1984) 478-483
53. Plotkin S.A., Starr S.E., Friedman H.M., Brayman K., Harris S., Jackson S., Tustin N.B., Grossman R., Dafoe D., and Barker C. Effect of Towne live virus vaccine on cytomegalovirus disease after renal transplant: a controlled trial. Ann Intern Med 114 (1991) 525-531
54. Plotkin S.A., Higgins R., Kurtz J.B., Morris P.J., Campbell Jr. D.A., Shope T.C., Spector S.A., and Dankner W.M. Multicenter trial of Towne strain attenuated virus vaccine in seronegative renal transplant recipients. Transplantation 58 (1994) 1176-1178
55. Balfour Jr. H.H., Sachs G.W., Welo P., Gehrz R.C., and Simmons R. Cytomegalovirus vaccine in renal transplant candidates: progress report of a randomized, placebo-controlled, double-blind trial. Birth Defects Orig Artic Ser 20 (1984) 289-304
56. Sachs G.W., Simmons R.L., and Balfour Jr. H.H. Cytomegalovirus vaccine: persistence of humoral immunity following immunization of renal transplant candidates. Vaccine 2 (1984) 215-218
57. Kemble G., Duke G., Winter R., and Spaete R. Defined large-scale alterations of the human cytomegalovirus genome constructed by cotransfection of overlapping cosmids. J Virol 70 (1996) 2044-2048
58. Schleiss M.R., and Heineman T.C. Progress toward an elusive goal: current status of cytomegalovirus vaccines. Expert Rev Vaccines 4 (2005) 381-406
59. Heineman T.C., Schleiss M., Bernstein D.I., Spaete R.R., Yan L., Duke G., Prichard M., Wang Z., Yan Q., Sharp M.A., Klein N., Arvin A.M., and Kemble G. A phase 1 study of 4 live, recombinant human cytomegalovirus Towne/Toledo chimeric vaccines. J Infect Dis 193 (2006) 1350-1360
60. Spaete R.R., Thayer R.M., Probert W.S., Masiarz F.R., Chamberlain S.H., Rasmussen L., Merigan T.C., and Pachl C. Human cytomegalovirus strain Towne glycoprotein B is processed by proteolytic cleavage. Virology 167 (1988) 207-225
61. Spaete R.R. A recombinant subunit vaccine approach to HCMV vaccine development. Transplant Proc 23 3 Suppl 3 (1991) 90-96
62. Pass R.F., Duliege A.M., Boppana S., Sekulovich R., Percell S., Britt W., and Burke R.L. A subunit cytomegalovirus vaccine based on recombinant envelope glycoprotein B and a new adjuvant. J Infect Dis 180 (1999) 970-975
63. Frey S.E., Harrison C., Pass R.F., Yang E., Boken D., Sekulovich R.E., Percell S., Izu A.E., Hirabayashi S., Burke R.L., and Duliege A.M. Effects of antigen dose and immunization regimens on antibody responses to a cytomegalovirus glycoprotein B subunit vaccine. J Infect Dis 180 (1999) 1700-1703
64. Mitchell D.K., Holmes S.J., Burke R.L., Duliege A.M., and Adler S.P. Immunogenicity of a recombinant human cytomegalovirus gB vaccine in seronegative toddlers. Pediatr Infect Dis J 21 (2002) 133-138
65. Zhang C., and Pass R.F. Detection of cytomegalovirus infection during clinical trials of glycoprotein B vaccine. Vaccine 23 (2004) 507-510
66. Temperton N.J. DNA vaccines against cytomegalovirus: current progress. Int J Antimicrob Agents 19 (2002) 169-172
67. Vilalta A., Mahajan R.K., Hartikka J., Rusalov D., Martin T., Bozoukova V., Leamy V., Hall K., Lalor P., Rolland A., and Kaslow D.C.I. Poloxamer-formulated plasmid DNA-based human cytomegalovirus vaccine: evaluation of plasmid DNA biodistribution/persistence and integration. Hum Gene Ther 16 (2005) 1143-1150
68. Selinsky C., Luke C., Wloch M., Geall A., Hermanson G., Kaslow D., and Evans T. A DNA-based vaccine for the prevention of human cytomegalovirus-associated diseases. Hum Vaccines 1 (2005) 16-23
69. Adler S.P., Plotkin S.A., Gonczol E., Cadoz M., Meric C., Wang J.B., Dellamonica P., Best A.M., Zahradnik J., Pincus S., Berencsi K., Cox W.I., and Gyulai Z. A canarypox vector expressing cytomegalovirus (CMV) glycoprotein B primes for antibody responses to a live attenuated CMV vaccine (Towne). J Infect Dis 180 (1999) 843-846
70. Bernstein D.I., Schleiss M.R., Berencsi K., Gonczol E., Dickey M., Khoury P., Cadoz M., Meric C., Zahradnik J., Duliege A.M., and Plotkin S. Effect of previous or simultaneous immunization with canarypox expressing cytomegalovirus (CMV) glycoprotein B (gB) on response to subunit gB vaccine plus MF59 in healthy CMV-seronegative adults. J Infect Dis 185 (2002) 686-690
71. Berencsi K., Gyulai Z., Gonczol E., Pincus S., Cox W.I., Michelson S., Kari L., Meric C., Cadoz M., Zahradnik J., Starr S., and Plotkin S. A canarypox vector-expressing cytomegalovirus (CMV) phosphoprotein 65 induces long-lasting cytotoxic T cell responses in human CMV-seronegative subjects. J Infect Dis 183 (2001) 1171-1179
72. Wang Z., Rosa C.L., Li Z., Ly H., Krishnan A., Martinez J., Britt W.J., and Diamond D.J. Vaccine properties of a novel marker gene-free recombinant modified vaccinia Ankara expressing immunodominant CMV antigens pp65 and IE1. Vaccine 25 (2007) 1132-1141
73. Schleiss M.R., Lacayo J., Belkaid Y., McGregor A., Stroup G., Rayner J., Alterson K., Chulay J.D., and Smith J.F. Preconceptual administration of an alphavirus replicon UL83 (pp65 homolog) vaccine induces humoral and cellular immunity and improves pregnancy outcome in the guinea pig model of congenital cytomegalovirus infection. J Infect Dis 195 (2007) 789-798
74. Nigro G., Adler S.P., La Torre R., Best A.M., and Congenital Cytomegalovirus Collaborating Group. Passive immunization during pregnancy for congenital cytomegalovirus infection. N Engl J Med 353 (2005) 1350-1362
75. La Torre R., Nigro G., Mazzocco M., Best A.M., and Adler S.P. Placental enlargement in women with primary maternal cytomegalovirus infection is associated with fetal and neonatal disease. Clin Infect Dis 43 (2006) 994-1000
76. Schleiss M.R. The role of the placenta in the pathogenesis of congenital cytomegalovirus infection: is the benefit of cytomegalovirus immune globulin for the newborn mediated through improved placental health and function?. Clin Infect Dis 43 (2006) 1001-1003
77. Zanghellini F., Boppana S.B., Emery V.C., Griffiths P.D., and Pass R.F. Asymptomatic primary cytomegalovirus infection: virologic and immunologic features. J Infect Dis 180 (1999) 702-707
78. Stanberry L.R., Rosenthal S.L., Mills L., Succop P.A., Biro F.M., Morrow R.A., and Bernstein D.I. Longitudinal risk of herpes simplex virus (HSV) type 1, HSV type 2, and cytomegalovirus infections among young adolescent girls. Clin Infect Dis 39 (2004) 1433-1438
79. Kumar M.L., Gold E., Jacobs I.B., Ernhart C.B., and Nankervis G.A. Primary cytomegalovirus infection in adolescent pregnancy. Pediatrics 74 (1984) 493-500
80. In: Stratton K.R., Durch J.S., and Lawrence R.S. (Eds). Vaccines for the 21st Century: A Tool for Decision making, Committee to Study Priorities for Vaccine Development, Division of Health Promotion and Disease Prevention, Institute of Medicine, Washington, DC (1999)
81. Meissner H.C., Reef S.E., and Cochi S. Elimination of rubella from the United States: a milestone on the road to global elimination. Pediatrics 117 (2006) 933-935
82. Griffiths P.D., McLean A., and Emery V.C. Encouraging prospects for immunisation against primary cytomegalovirus infection. Vaccine 19 (2001) 1356-1362
83. Soderberg-Naucler C. Does cytomegalovirus play a causative role in the development of various inflammatory diseases and cancer?. J Intern Med 259 (2006) 219-246
84. Cannon M.J., and Davis K.F. Washing our hands of the congenital cytomegalovirus disease epidemic. BMC Public Health 5 (2005) 70
85. Casteels A., Naessens A., Gordts F., De Catte L., Bougatef A., and Foulon W. Neonatal screening for congenital cytomegalovirus infections. J Perinatal Med 27 (1999) 116-121
86. Barbi M., Binda S., Caroppo S., and Primache V. Neonatal screening for congenital cytomegalovirus infection and hearing loss. J Clin Virol 35 (2006) 206-209
87. Collinet P., Subtil D., Houfflin-Debarge V., Kacet N., Dewilde A., and Puech F. Routine CMV screening during pregnancy. Eur J Obstet Gynecol Reprod Biol 114 (2004) 3-11
88. ACOG practice bulletin. Perinatal viral and parasitic infections. Number 20, September 2000. ACOG. International J Gynaecol Obstet 76 (2002) 95-107